High-Riding Patella Seen in ACL Reconstruction, Uninjured Contralateral Knees
By Elana Gotkine HealthDay Reporter
TUESDAY, March 25, 2025 -- In anterior cruciate ligament reconstruction (ACLR) and uninjured contralateral knees, the patella articulates higher on the femoral trochlea due primarily to a longer patellar tendon compared with healthy knees, according to a study published online March 19 in the Journal of Orthopaedic Research.
Marcus G. Pandy, Ph.D., from the University of Melbourne in Australia, and colleagues measured six‐degree‐of‐freedom patellofemoral and tibiofemoral motion in ACLR and uninjured contralateral knees during gait and compared the results to healthy knees. Six‐degree‐of‐freedom patellofemoral and tibiofemoral motion was measured in 15 ACLR participants and 10 healthy individuals for complete cycles of level walking and downhill walking.
The researchers found that compared with controls, mean patellar superior translation, anterior translation, and flexion over the gait cycle were 4.4 to 5.6 mm greater, 5.4 to 6.3 mm greater, and 3.7 to 7.0 degrees less, respectively, in the ACLR and contralateral knees across both activities. In the ACLR and contralateral knees versus controls, articular contact was 7.6 mm higher on the femoral trochlea. The patellar tendon was 8.9 mm longer in the ACLR and contralateral knees versus controls. Fourteen of 30 knees among ACLR participants had an Insall-Salvati ratio ≥1.20, indicating patella alta. Compared with controls, mean tibial external rotation and anterior translation over the gait cycle were 3.4 to 3.8 degrees greater and 2.6 to 3.0 mm greater in the ACLR knees across both walking and downhill walking.
"A higher riding patella may contribute to the development of patellofemoral osteoarthritis by shifting the load‐bearing areas on the femoral trochlea to regions of cartilage unaccustomed to load and leaving previously loaded regions underloaded," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.